{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:59:10Z","timestamp":1790258350907,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:p>Opsoclonus myoclonus syndrome (OMS), often called \u201cdancing eyed syndrome,\u201d is a rare neurological condition associated with neuroblastoma in the majority of all childhood cases. Genomic copy number profiles have shown to be of prognostic significance for neuroblastoma patients. The aim of this retrospective multicenter study was to analyze the genomic copy number profiles of tumors from children with neuroblastoma presenting with OMS at diagnosis. In 44 cases of neuroblastoma associated with OMS, overall genomic profiling by either array-comparative genomic hybridization or single nucleotide polymorphism array proved successful in 91% of the cases, distinguishing tumors harboring segmental chromosome alterations from those with numerical chromosome alterations only. A total of 23\/44 (52%) tumors showed an segmental chromosome alterations genomic profile, 16\/44 (36%) an numerical chromosome alterations genomic profile, and 1 case displayed an atypical profile (12q amplicon). No recurrently small interstitial copy number alterations were identified. With no tumor relapse nor disease-related deaths, the overall genomic profile was not of prognostic impact with regard to the oncological outcome in this series of patients. Thus, the observation of an excellent oncological outcome, even for those with an unfavorable genomic profile of neuroblastoma, supports the hypothesis that an immune response might be involved in tumor control in these patients with OMS.<\/jats:p>","DOI":"10.1097\/mph.0000000000000976","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T12:59:47Z","timestamp":1510664387000},"page":"93-98","source":"Crossref","is-referenced-by-count":15,"title":["Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome"],"prefix":"10.1097","volume":"40","author":[{"given":"Barbara","family":"Hero","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Children\u2019s Hospital, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Clement","sequence":"additional","affiliation":[{"name":"Team SiRIC Translational Research in Pediatric Oncology, Institut Curie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"\u00d8ra","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Skane University Hospital, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Pierron","sequence":"additional","affiliation":[{"name":"Genetic Somatic Unit, Department of Genetic and Biology of Cancers, Institut Curie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Lapouble","sequence":"additional","affiliation":[{"name":"Genetic Somatic Unit, Department of Genetic and Biology of Cancers, Institut Curie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Theissen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Children\u2019s Hospital, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pasqualini","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valteau-Couanet","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Plantaz","sequence":"additional","affiliation":[{"name":"CHU Grenoble, Department of Pediatric Hematology and Oncology, Grenoble"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Michon","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Institut Curie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Delattre","sequence":"additional","affiliation":[{"name":"Genetic Somatic Unit, Department of Genetic and Biology of Cancers, Institut Curie"},{"name":"INSERM U830, Genetic and Biology of Cancers, Institut Curie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tardieu","sequence":"additional","affiliation":[{"name":"H\u00f4pitaux Universitaires Paris Sud, Assistance publique-H\u00f4pitaux de Paris, Department of Pediatric Neurology Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Schleiermacher","sequence":"additional","affiliation":[{"name":"Team SiRIC Translational Research in Pediatric Oncology, Institut Curie"},{"name":"Department of Pediatric Oncology, Institut Curie"},{"name":"INSERM U830, Genetic and Biology of Cancers, Institut Curie"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.canlet.2005.01.051","article-title":"Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004","volume":"228","author":"Matthay","year":"2005","journal-title":"Cancer Lett"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0929-693X(00)80129-3","article-title":"Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists","volume":"7","author":"Plantaz","year":"2000","journal-title":"Arch Pediatr"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00002826-199206000-00002","article-title":"The neurobiology of the opsoclonus-myoclonus syndrome","volume":"15","author":"Pranzatelli","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0887-8994(02)00457-5","article-title":"Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia","volume":"27","author":"Pranzatelli","year":"2002","journal-title":"Pediatr Neurol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.62.9.1526","article-title":"B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes","volume":"62","author":"Pranzatelli","year":"2004","journal-title":"Neurology"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpn.2008.04.012","article-title":"Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma","volume":"13","author":"Raffaghello","year":"2009","journal-title":"Eur J Paediatr Neurol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00043426-200007000-00007","article-title":"Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus","volume":"22","author":"Antunes","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0887-8994(94)90127-9","article-title":"Anti-Hu antibody in a neuroblastoma-associated paraneoplastic syndrome","volume":"10","author":"Fisher","year":"1994","journal-title":"Pediatr Neurol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0165-5728(87)90088-9","article-title":"Anti-neurofilament protein antibodies in opsoclonus-myoclonus","volume":"15","author":"Noetzel","year":"1987","journal-title":"J Neuroimmunol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1126\/science.4039466","article-title":"Circulating autoantibodies to the 200,000-dalton protein of neurofilaments in the serum of healthy individuals","volume":"228","author":"Stefansson","year":"1985","journal-title":"Science"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1055\/s-0033-1358604","article-title":"Update on pediatric opsoclonus myoclonus syndrome","volume":"44","author":"Hero","year":"2013","journal-title":"Neuropediatrics"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/mpo.1138","article-title":"Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children\u2019s Cancer Group Study","volume":"36","author":"Rudnick","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/mpo.1139","article-title":"Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children\u2019s Cancer Group","volume":"36","author":"Cooper","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00428-002-0747-1","article-title":"Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases","volume":"442","author":"Gambini","year":"2003","journal-title":"Virchows Arch"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1542\/peds.2010-3114","article-title":"Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life","volume":"128","author":"Brunklaus","year":"2011","journal-title":"Pediatrics"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/onc.2009.518","article-title":"Molecular pathogenesis of peripheral neuroblastic tumors","volume":"29","author":"Janoueix-Lerosey","year":"2010","journal-title":"Oncogene"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMra0804577","article-title":"Recent advances in neuroblastoma","volume":"362","author":"Maris","year":"2010","journal-title":"N Engl J Med"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM199601253340404","article-title":"Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma","volume":"334","author":"Caron","year":"1996","journal-title":"N Engl J Med"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.1991.9.4.581","article-title":"Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study","volume":"9","author":"Look","year":"1991","journal-title":"J Clin Oncol"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0215(19960422)69:2<73::AID-IJC1>3.0.CO;2-S","article-title":"Clinical relevance of loss heterozygosity of the short arm of chromosome 1 in neuroblastoma: a single-institution study","volume":"69","author":"Schleiermacher","year":"1996","journal-title":"Int J Cancer"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/gcc.2870100409","article-title":"Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma","volume":"10","author":"Schleiermacher","year":"1994","journal-title":"Genes Chromosomes Cancer"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cancergen.2013.02.003","article-title":"MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma","volume":"206","author":"Bourdeaut","year":"2013","journal-title":"Cancer Genet"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1200\/JCO.2008.16.0630","article-title":"Overall genomic pattern is a predictor of outcome in neuroblastoma","volume":"27","author":"Janoueix-Lerosey","year":"2009","journal-title":"J Clin Oncol"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/gcc.22174","article-title":"Chromosome 17\/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma","volume":"53","author":"Theissen","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/bioinformatics\/btl359","article-title":"VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles","volume":"22","author":"La Rosa","year":"2006","journal-title":"Bioinformatics"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.2009.26.7955","article-title":"Accumulation of segmental alterations determines progression in neuroblastoma","volume":"28","author":"Schleiermacher","year":"2010","journal-title":"J Clin Oncol"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/sj.bjc.6605014","article-title":"International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee","volume":"100","author":"Ambros","year":"2009","journal-title":"Br J Cancer"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/bjc.2011.472","article-title":"Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable\/disseminated neuroblastoma (a SIOPEN collaborative study)","volume":"105","author":"Schleiermacher","year":"2011","journal-title":"Br J Cancer"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/adc.2010.204792","article-title":"Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome","volume":"97","author":"Brunklaus","year":"2012","journal-title":"Arch Dis Child"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejpn.2009.12.005","article-title":"Opsoclonus-myoclonus in children associated or not with neuroblastoma","volume":"14","author":"Krug","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/bjc.2014.557","article-title":"Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification","volume":"112","author":"Defferrari","year":"2015","journal-title":"Br J Cancer"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/mds.20125","article-title":"CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity","volume":"19","author":"Pranzatelli","year":"2004","journal-title":"Mov Disord"},{"key":"R34-20230918","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2009.03.006","article-title":"Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome","volume":"210","author":"Fuhlhuber","year":"2009","journal-title":"J Neuroimmunol"},{"key":"R35-20230918","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1742-2094-10-10","article-title":"BAFF\/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy","volume":"10","author":"Pranzatelli","year":"2013","journal-title":"J Neuroinflammation"},{"key":"R36-20230918","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1189\/jlb.0213106","article-title":"Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity","volume":"94","author":"Raffaghello","year":"2013","journal-title":"J Leukoc Biol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201803000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:13:38Z","timestamp":1694996018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201803000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000976","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}